Potential metabolite markers of schizophrenia

J. Yang, T. Chen, L. Sun, Z. Zhao, X. Qi, K. Zhou, Y. Cao, X. Wang, Yunping Qiu, M. Su, A. Zhao, P. Wang, P. Yang, J. Wu, G. Feng, L. He, W. Jia, C. Wan

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Schizophrenia is a severe mental disorder that affects 0.5-1% of the population worldwide. Current diagnostic methods are based on psychiatric interviews, which are subjective in nature. The lack of disease biomarkers to support objective laboratory tests has been a long-standing bottleneck in the clinical diagnosis and evaluation of schizophrenia. Here we report a global metabolic profiling study involving 112 schizophrenic patients and 110 healthy subjects, who were divided into a training set and a test set, designed to identify metabolite markers. A panel of serum markers consisting of glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine was identified as an effective diagnostic tool, achieving an area under the receiver operating characteristic curve (AUC) of 0.945 in the training samples (62 patients and 62 controls) and 0.895 in the test samples (50 patients and 48 controls). Furthermore, a composite panel by the addition of urine β-hydroxybutyrate to the serum panel achieved a more satisfactory accuracy, which reached an AUC of 1 in both the training set and the test set. Multiple fatty acids and ketone bodies were found significantly (P0.01) elevated in both the serum and urine of patients, suggesting an upregulated fatty acid catabolism, presumably resulting from an insufficiency of glucose supply in the brains of schizophrenia patients.

Original languageEnglish (US)
Pages (from-to)67-78
Number of pages12
JournalMolecular Psychiatry
Volume18
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Schizophrenia
Hydroxybutyrates
Area Under Curve
Fatty Acids
Biomarkers
Urine
Ketone Bodies
Cystine
Serum
Pyruvic Acid
Mental Disorders
ROC Curve
Psychiatry
Healthy Volunteers
Interviews
Glucose
Brain
Population

Keywords

  • biomarker
  • GC-TOFMS
  • metaobonomics
  • NMR
  • schizophrenia

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Yang, J., Chen, T., Sun, L., Zhao, Z., Qi, X., Zhou, K., ... Wan, C. (2013). Potential metabolite markers of schizophrenia. Molecular Psychiatry, 18(1), 67-78. https://doi.org/10.1038/mp.2011.131

Potential metabolite markers of schizophrenia. / Yang, J.; Chen, T.; Sun, L.; Zhao, Z.; Qi, X.; Zhou, K.; Cao, Y.; Wang, X.; Qiu, Yunping; Su, M.; Zhao, A.; Wang, P.; Yang, P.; Wu, J.; Feng, G.; He, L.; Jia, W.; Wan, C.

In: Molecular Psychiatry, Vol. 18, No. 1, 01.2013, p. 67-78.

Research output: Contribution to journalArticle

Yang, J, Chen, T, Sun, L, Zhao, Z, Qi, X, Zhou, K, Cao, Y, Wang, X, Qiu, Y, Su, M, Zhao, A, Wang, P, Yang, P, Wu, J, Feng, G, He, L, Jia, W & Wan, C 2013, 'Potential metabolite markers of schizophrenia', Molecular Psychiatry, vol. 18, no. 1, pp. 67-78. https://doi.org/10.1038/mp.2011.131
Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K et al. Potential metabolite markers of schizophrenia. Molecular Psychiatry. 2013 Jan;18(1):67-78. https://doi.org/10.1038/mp.2011.131
Yang, J. ; Chen, T. ; Sun, L. ; Zhao, Z. ; Qi, X. ; Zhou, K. ; Cao, Y. ; Wang, X. ; Qiu, Yunping ; Su, M. ; Zhao, A. ; Wang, P. ; Yang, P. ; Wu, J. ; Feng, G. ; He, L. ; Jia, W. ; Wan, C. / Potential metabolite markers of schizophrenia. In: Molecular Psychiatry. 2013 ; Vol. 18, No. 1. pp. 67-78.
@article{5642ac2becd64116962adf4b56dd8557,
title = "Potential metabolite markers of schizophrenia",
abstract = "Schizophrenia is a severe mental disorder that affects 0.5-1{\%} of the population worldwide. Current diagnostic methods are based on psychiatric interviews, which are subjective in nature. The lack of disease biomarkers to support objective laboratory tests has been a long-standing bottleneck in the clinical diagnosis and evaluation of schizophrenia. Here we report a global metabolic profiling study involving 112 schizophrenic patients and 110 healthy subjects, who were divided into a training set and a test set, designed to identify metabolite markers. A panel of serum markers consisting of glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine was identified as an effective diagnostic tool, achieving an area under the receiver operating characteristic curve (AUC) of 0.945 in the training samples (62 patients and 62 controls) and 0.895 in the test samples (50 patients and 48 controls). Furthermore, a composite panel by the addition of urine β-hydroxybutyrate to the serum panel achieved a more satisfactory accuracy, which reached an AUC of 1 in both the training set and the test set. Multiple fatty acids and ketone bodies were found significantly (P0.01) elevated in both the serum and urine of patients, suggesting an upregulated fatty acid catabolism, presumably resulting from an insufficiency of glucose supply in the brains of schizophrenia patients.",
keywords = "biomarker, GC-TOFMS, metaobonomics, NMR, schizophrenia",
author = "J. Yang and T. Chen and L. Sun and Z. Zhao and X. Qi and K. Zhou and Y. Cao and X. Wang and Yunping Qiu and M. Su and A. Zhao and P. Wang and P. Yang and J. Wu and G. Feng and L. He and W. Jia and C. Wan",
year = "2013",
month = "1",
doi = "10.1038/mp.2011.131",
language = "English (US)",
volume = "18",
pages = "67--78",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Potential metabolite markers of schizophrenia

AU - Yang, J.

AU - Chen, T.

AU - Sun, L.

AU - Zhao, Z.

AU - Qi, X.

AU - Zhou, K.

AU - Cao, Y.

AU - Wang, X.

AU - Qiu, Yunping

AU - Su, M.

AU - Zhao, A.

AU - Wang, P.

AU - Yang, P.

AU - Wu, J.

AU - Feng, G.

AU - He, L.

AU - Jia, W.

AU - Wan, C.

PY - 2013/1

Y1 - 2013/1

N2 - Schizophrenia is a severe mental disorder that affects 0.5-1% of the population worldwide. Current diagnostic methods are based on psychiatric interviews, which are subjective in nature. The lack of disease biomarkers to support objective laboratory tests has been a long-standing bottleneck in the clinical diagnosis and evaluation of schizophrenia. Here we report a global metabolic profiling study involving 112 schizophrenic patients and 110 healthy subjects, who were divided into a training set and a test set, designed to identify metabolite markers. A panel of serum markers consisting of glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine was identified as an effective diagnostic tool, achieving an area under the receiver operating characteristic curve (AUC) of 0.945 in the training samples (62 patients and 62 controls) and 0.895 in the test samples (50 patients and 48 controls). Furthermore, a composite panel by the addition of urine β-hydroxybutyrate to the serum panel achieved a more satisfactory accuracy, which reached an AUC of 1 in both the training set and the test set. Multiple fatty acids and ketone bodies were found significantly (P0.01) elevated in both the serum and urine of patients, suggesting an upregulated fatty acid catabolism, presumably resulting from an insufficiency of glucose supply in the brains of schizophrenia patients.

AB - Schizophrenia is a severe mental disorder that affects 0.5-1% of the population worldwide. Current diagnostic methods are based on psychiatric interviews, which are subjective in nature. The lack of disease biomarkers to support objective laboratory tests has been a long-standing bottleneck in the clinical diagnosis and evaluation of schizophrenia. Here we report a global metabolic profiling study involving 112 schizophrenic patients and 110 healthy subjects, who were divided into a training set and a test set, designed to identify metabolite markers. A panel of serum markers consisting of glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine was identified as an effective diagnostic tool, achieving an area under the receiver operating characteristic curve (AUC) of 0.945 in the training samples (62 patients and 62 controls) and 0.895 in the test samples (50 patients and 48 controls). Furthermore, a composite panel by the addition of urine β-hydroxybutyrate to the serum panel achieved a more satisfactory accuracy, which reached an AUC of 1 in both the training set and the test set. Multiple fatty acids and ketone bodies were found significantly (P0.01) elevated in both the serum and urine of patients, suggesting an upregulated fatty acid catabolism, presumably resulting from an insufficiency of glucose supply in the brains of schizophrenia patients.

KW - biomarker

KW - GC-TOFMS

KW - metaobonomics

KW - NMR

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84871291341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871291341&partnerID=8YFLogxK

U2 - 10.1038/mp.2011.131

DO - 10.1038/mp.2011.131

M3 - Article

VL - 18

SP - 67

EP - 78

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 1

ER -